Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 20:04:13 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Isofol Medical - AGENT on a Mission to Secure Critical Data

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Isofol Medical - AGENT on a Mission to Secure Critical Data

2021-11-15 10:00:00

Redeye revisits its view on Isofol ahead of the make-or-break phase III AGENT top-line data for its only pipeline asset, arfolitixorin, in H1 2022. We maintain our positive view on the case and anticipate a successful trial readout. In anticipation of AGENT top-line data, we judge the share could rally to our new Base Case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/